North America Nucleic Acid Amplification Testing Market Report by Type, Application, End Use, Country and Company Analysis, 2026-2034

North America Nucleic Acid Amplification Testing Market Size and Forecast

North America Nucleic Acid Amplification Testing Market is projected to grow from US$ 3.28 Billion in 2025 to US$ 7.65 Billion by 2034, expanding at a Compound Annual Growth Rate (CAGR) of 9.87% during 2026–2034. Market growth is driven by the increasing prevalence of infectious diseases, rising demand for rapid and accurate molecular diagnostics, technological advancements in nucleic acid amplification technologies, and greater adoption of point-of-care testing. Additionally, growing healthcare expenditure and improved diagnostic infrastructure are supporting market expansion across North America.

What is Nucleic Acid Amplification Testing and Its Uses & Popularity in North America

Nucleic Acid Amplification Testing (NAAT) is a molecular diagnostic technique used to identify specific DNA or RNA sequences by amplifying tiny quantities of genetic material, enabling the detection of pathogens and genetic abnormalities with high sensitivity. Common methods include polymerase chain reaction (PCR), reverse-transcription PCR (RT-PCR), loop-mediated isothermal amplification (LAMP), and transcription-mediated amplification.  In North America, NAAT is widely used for diagnosing respiratory infections, sexually transmitted infections, gastrointestinal diseases, and other infectious conditions, while its applications are expanding into oncology and genetic testing. Growing availability of point-of-care and multiplex molecular tests is further increasing NAAT adoption across hospitals, diagnostic laboratories, clinics, and public-health programs.

U.S. HIV Statistics

• Approximately 1.2 million people in the U.S. have HIV. About 13 percent of them don’t know it and need testing.
• HIV continues to have a disproportionate impact on certain populations, particularly racial and ethnic minorities and gay, bisexual, and other men who have sex with men (MSM).
• In 2022, an estimated 31,800 people acquired HIV in the U.S.
• Estimated new HIV infections decreased 12% from 36,300 in 2018 to 31,800 in 2022.
• In 2022, 37,981 people aged ≥ 13 and older received an HIV diagnosis in the U.S. and 6 territories and freely associated states.
• HIV diagnoses are not evenly distributed across states and regions. The highest rates of new diagnoses continue to occur in the South.

Canada’s Updated STBBI Action Plan Strengthens National Prevention and Testing Efforts

In 2019, the Government of Canada introduced a five-year action plan to advance the national framework for sexually transmitted and blood-borne infections (STBBI). The initiative, titled Accelerating Our Response: Government of Canada Five-Year Action Plan on Sexually Transmitted and Blood-Borne Infections (2019–2024), established a coordinated approach to improving prevention, diagnosis, treatment, and support for people affected by STBBI.

In 2024, Canada introduced an updated STBBI Action Plan for 2024–2030, designed to accelerate national efforts to prevent, diagnose, and treat STBBI while reducing barriers to healthcare access. The renewed plan identifies 16 federal priorities and 49 actions, supported by indicators for monitoring progress. These priorities correspond with four core areas: prevention, testing, treatment initiation, and continuing care and support, underpinned by an enabling environment. Implementation involves nine federal departments, reflecting a coordinated whole-of-government strategy. The Government of Canada also emphasizes collaboration with key populations, communities, and partners to advance shared STBBI priorities and strengthen access to appropriate care and services.

Growth Drivers of the North America Nucleic Acid Amplification Testing Market

Rising Demand for Rapid and Highly Sensitive Molecular Diagnostics

Increasing demand for accurate, sensitive, and rapid disease detection is a major growth driver for the North America NAAT market. NAATs can detect very small quantities of pathogen genetic material, making them particularly valuable when conventional diagnostic methods may have lower sensitivity. The CDC notes that molecular NAATs generally offer greater sensitivity than antigen tests for respiratory viruses, while some point-of-care NAATs can deliver results rapidly. This performance is encouraging adoption in hospitals, physician offices, diagnostic laboratories, and decentralized testing environments. In addition, NAATs are increasingly used for respiratory infections, sexually transmitted infections, and other infectious diseases. The ability to identify infections earlier and support appropriate treatment decisions is strengthening their clinical value and contributing to continued market expansion.

Expansion of Infectious Disease Testing and Surveillance

The persistent burden of infectious diseases across North America is creating sustained demand for nucleic acid amplification testing. Infectious-disease testing was the largest NAAT application segment in North America in 2024.  NAATs are extensively used to detect respiratory viruses, including influenza, respiratory syncytial virus (RSV), SARS-CoV-2, adenovirus, and other pathogens. The CDC’s National Respiratory and Enteric Virus Surveillance System currently receives laboratory-based surveillance data from more than 450 public-health and clinical laboratories across the United States. This extensive surveillance infrastructure supports continued utilization of molecular testing for pathogen monitoring and outbreak detection. Beyond respiratory diseases, NAATs are used for sexually transmitted infections, mosquito-borne diseases, gastrointestinal infections, and other conditions. The increasing emphasis on early diagnosis, infection control, and public-health preparedness is therefore supporting demand for high-performance molecular testing platforms throughout the United States and Canada.

Technological Advancements and Point-of-Care Testing

Rapid technological innovation is transforming NAAT platforms and expanding their use beyond centralized laboratories. Advances in automation, multiplex testing, isothermal amplification, miniaturized instruments, and point-of-care systems are making molecular testing faster and more accessible. The CDC reports that NAATs can be performed in laboratories, point-of-care settings, and, for certain products, at home or other non-healthcare locations. The emergence of multiplex molecular assays is particularly important because a single test can identify multiple respiratory pathogens, improving diagnostic efficiency. In addition, FDA-regulated molecular testing continues to expand; the FDA maintains lists of cleared and approved nucleic-acid-based tests covering microbial and human genetic applications. Continued innovation in speed, portability, automation, and multiplexing should further broaden adoption.

Challenges of the North America Nucleic Acid Amplification Testing Market

High Testing Costs and Complex Infrastructure Requirements

High equipment, reagent, maintenance, and laboratory infrastructure costs remain important challenges for NAAT adoption. Although molecular testing offers high sensitivity and specificity, sophisticated platforms can require substantial capital investment, trained personnel, controlled laboratory environments, and regular quality assurance. These requirements can create financial barriers for smaller hospitals, independent laboratories, and facilities serving geographically remote populations. NAAT performance can also vary according to the technology and testing setting. The CDC notes that laboratory-based NAATs generally have higher sensitivity than point-of-care or self-administered tests, while turnaround times can range from less than an hour to more than a day depending on the test. This variation creates a trade-off between speed, sensitivity, cost, and operational complexity. In addition, laboratories must maintain instruments, procure specialized reagents, manage quality-control procedures, and train technical staff. Consequently, despite strong market growth, cost optimization and simplified testing workflows remain essential for wider deployment of advanced NAAT platforms.

Regulatory Complexity and Testing Standardization

Regulatory requirements, validation procedures, and the need for consistent performance can slow the commercialization and adoption of new NAAT technologies. Molecular diagnostic manufacturers must demonstrate analytical and clinical performance before obtaining appropriate regulatory clearance or approval, while laboratories must maintain quality-control and testing standards. The FDA maintains dedicated classifications and lists for nucleic-acid-based diagnostic tests, including microbial and human genetic tests, demonstrating the breadth of regulatory oversight surrounding these products. Emerging technologies such as multiplex assays, decentralized testing, and at-home molecular diagnostics can introduce additional considerations involving usability, specimen collection, analytical sensitivity, and result interpretation. For example, FDA’s classification of over-the-counter molecular multi-analyte respiratory virus tests specifically covers devices using nucleic acid amplification technology for detecting or differentiating respiratory viruses. As NAAT applications expand, manufacturers must balance innovation with regulatory compliance, while healthcare providers need standardized workflows and interpretation practices. These factors can increase development timelines and costs and represent a continuing challenge for market participants.

Nucleic Acid Amplification Testing Launches in North America

1. cobas liat CT/NG/MG Nucleic Acid Test – Roche
   Roche’s cobas liat CT/NG/MG is designed to detect Chlamydia trachomatis, Neisseria gonorrhoeae, and Mycoplasma genitalium. The FDA granted 510(k) clearance on May 2026, supporting expanded molecular testing for sexually transmitted infections.
2. Xpert Carba-R – Cepheid
   Cepheid’s Xpert Carba-R is a multiplex NAAT designed to detect major carbapenemase genes associated with antimicrobial-resistant Enterobacterales. The FDA cleared the test on July 2026, strengthening molecular surveillance for antimicrobial resistance.
3. Alinity m HIV-1 AMP Kit – Abbott
   Abbott’s Alinity m HIV-1 AMP Kit received FDA clearance in August 2025 for use with the Alinity m system. The launch expands automated molecular testing capabilities for HIV-1 detection and monitoring.
4. Alinity m HCV – Abbott
   Abbott’s Alinity m HCV is a molecular assay for detecting hepatitis C virus RNA. The FDA granted 510(k) clearance on September 25, 2025, adding another infectious-disease application to the Alinity m molecular testing platform.
5. LIAISON NES FLU A/B, RSV & COVID-19 – DiaSorin Molecular
   DiaSorin’s LIAISON NES FLU A/B, RSV & COVID-19 is a multi-target respiratory nucleic acid test covering influenza A/B, RSV, and SARS-CoV-2. The FDA cleared the test on December 2025, supporting multiplex respiratory diagnostics.
6. QIAstat-Dx Respiratory Panel Plus/Mini – QIAGEN
   QIAGEN received FDA clearance in August 2025 for the QIAstat-Dx Respiratory Panel Plus and Mini. These systems provide multiplex molecular detection of respiratory pathogens, helping laboratories evaluate several potential causes of respiratory illness from a single specimen.
7. cobas HIV-1/HIV-2 Qualitative Nucleic Acid Test – Roche
   Roche’s cobas HIV-1/HIV-2 qualitative NAAT for the cobas 5800/6800/8800 systems received FDA clearance in June 2025. The assay expands qualitative molecular testing capabilities for HIV infection.
8. cobas HIV-1 Quantitative Nucleic Acid Test – Roche
   Roche also received FDA clearance in July 2025 for its cobas HIV-1 quantitative nucleic acid test for use on the cobas 5800/6800/8800 platforms. The test supports molecular quantification of HIV-1.
9. cobas liat SARS-CoV-2 v2 Nucleic Acid Test – Roche
   Roche’s cobas liat SARS-CoV-2 v2 is a point-of-care molecular test designed to detect SARS-CoV-2 nucleic acid. The FDA granted 510(k) clearance in April 2025, supporting near-patient molecular respiratory testing.
10. APTIMA HPV Assay – Hologic/Gen-Probe
    The APTIMA HPV Assay is an established NAAT that detects E6/E7 messenger RNA from 14 high-risk HPV types in cervical specimens. In February 2026, the FDA approved a PMA supplement involving updated indications, instructions, shelf life, and trade-name information.

United States Advanced Healthcare Infrastructure and Molecular Diagnostics Adoption

United States Nucleic Acid Amplification Testing (NAAT) Market remains the dominant market in North America, supported by advanced healthcare infrastructure, extensive laboratory networks, and rapid adoption of molecular diagnostic technologies. Infectious disease testing represents a major application, while NAAT is also increasingly utilized in oncology, genetic testing, and precision medicine. According to market estimates, the U.S. NAAT market is expected to expand significantly through 2034, supported by rising demand for rapid and highly sensitive diagnostics. The country’s strong biotechnology ecosystem and presence of major diagnostic companies encourage continuous development of automated, multiplex, and point-of-care testing platforms. Government investments in infectious-disease surveillance and laboratory preparedness further strengthen demand. In addition, increasing healthcare expenditure and growing awareness of early disease detection are supporting testing volumes. Although reimbursement complexity, regulatory requirements, and relatively high testing costs remain challenges, technological advancements are improving efficiency and accessibility. Consequently, the United States continues to serve as the primary innovation and revenue center for NAAT across North America.

Canada Healthcare Modernization and Public Health Testing Support

Canada Nucleic Acid Amplification Testing Market is experiencing steady expansion as healthcare providers increasingly adopt molecular diagnostics for infectious diseases, genetic disorders, and preventive screening. Canada’s publicly funded healthcare system, combined with investments in laboratory modernization and disease surveillance, supports the broader utilization of NAAT technologies. Respiratory infections, sexually transmitted infections, and other communicable diseases remain important testing applications, while molecular approaches are also gaining relevance in personalized medicine. Canada’s diagnostic infrastructure benefits from collaboration among government agencies, universities, research institutions, and biotechnology companies, encouraging technology development and clinical adoption. However, geographic differences in healthcare access, particularly between major urban centers and remote communities, can create testing availability challenges. Canada is also emphasizing improved laboratory capacity and digital healthcare integration to strengthen diagnostic services. Growing awareness of rapid molecular testing and continued public-health preparedness are expected to support market development. With increasing investment in accessible, accurate, and efficient diagnostics, Canada is positioned to remain an important contributor to North America’s NAAT market growth.

Market Segmentations

Type

• Polymerase Chain Reaction (PCR) Tests
• Isothermal Nucleic Acid Amplification Technology (INAAT) Tests
• Ligase Chain Reaction (LCR) Tests

Application

• Infectious Disease Testing
• Oncology Testing
• Others

End Use

• Central & Reference Laboratories
• Hospitals
• Others

Country

• United States
• Canada

All the Key players have been covered

• Overviews
• Key Person
• Recent Developments
• SWOT Analysis
• Revenue Analysis

Company Analysis:

• F. Hoffmann-La Roche Ltd
• Becton, Dickinson and Company
• Danaher Corporation
• Abbott Laboratories
• Illumina, Inc.
• Siemens Healthineers
• bioMérieux SA
• Novartis AG
• Bio-Rad Laboratories, Inc.
• Seegene Inc.

Report Details: